风险适应性方法可否支持高危复发透明细胞肾细胞癌患者辅助帕博利珠单抗治疗资格的共享决策:一项多中心队列研究
该多中心队列研究纳入2015至2021年接受手术的非转移性肾肿块患者,识别符合KEYNOTE-564标准的透明细胞肾细胞癌病例,采用Stewart-Merrill风险适应性模型分层,评估因其他原因死亡风险超过肾癌复发风险而可能不适合辅助帕博利珠单抗的患者比例。共1745例患者纳入,其中419例(24%)符合KEYNOTE-564标准;在推荐随访≤2.0、≤5、≤10和≤20年时,因其他原因死亡概率高于复发概率而“不适合”辅助帕博利珠单抗的比例分别为81%、66%、43%和29%。
要点
- 共1745例透明细胞肾细胞癌患者纳入,419例(24%)符合KEYNOTE-564标准。
- 在推荐随访≤2.0、≤5、≤10和≤20年时,因其他原因死亡概率高于复发概率而“不适合”辅助帕博利珠单抗的比例分别为81%、66%、43%和29%。
- 比较其他原因死亡风险与肾癌复发风险可能有助于减少对可能无法获益患者的过度治疗。
核心结论
- 据作者所知,这是首个为非转移性透明细胞肾细胞癌患者辅助帕博利珠单抗治疗资格的共享决策提供见解的研究,关注肿瘤驱动预后评分之外的患者相关因素。
研究设计与样本
- 多中心队列研究,查询前瞻性收集的多机构数据库,纳入2015至2021年接受手术的非转移性肾肿块(cT1-4 N0-1 M0)连续患者,识别符合KEYNOTE-564标准的透明细胞肾细胞癌病例。
- 采用Stewart-Merrill等提出的风险适应性模型分层,即当估计的其他原因死亡风险超过估计的肾癌复发风险时,停止随访是合理的。
- 共1745例透明细胞肾细胞癌患者纳入,其中419例(24%)符合KEYNOTE-564标准。
主要发现
- 在推荐随访≤2.0年时,因其他原因死亡概率高于肾癌复发概率而“不适合”辅助帕博利珠单抗的患者比例为81%。
- 在推荐随访≤5年时,因其他原因死亡概率高于肾癌复发概率而“不适合”辅助帕博利珠单抗的患者比例为66%。
- 在推荐随访≤10年时,因其他原因死亡概率高于肾癌复发概率而“不适合”辅助帕博利珠单抗的患者比例为43%。
- 在推荐随访≤20年时,因其他原因死亡概率高于肾癌复发概率而“不适合”辅助帕博利珠单抗的患者比例为29%。
关键数值与推荐
- KEYNOTE-564随机对照试验显示,与安慰剂相比,辅助帕博利珠单抗在高复发风险透明细胞肾细胞癌患者中具有无病生存获益。
- 尽管欧洲泌尿外科学会指南推荐辅助帕博利珠单抗,但其最终价值近期受到质疑。
临床怎么用
- 作者认为,比较其他原因死亡风险与肾癌复发风险可能有助于减少对可能无法获益患者的过度治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The KEYNOTE-564 randomised controlled trial showed a disease-free survival benefit of adjuvant pembrolizumab (aPZB) in comparison to placebo for patients with clear cell renal cell carcinoma (ccRCC) at high risk of recurrence. Despite its recommendation by the European Association of Urology guidelines, the ultimate value of aPZB has recently been questioned. Arguably, patients who might benefit the most from aPZB are those whose probability of RCC recurrence outweighs their probability of dying from other causes over a reasonable timeframe after surgery. To assess the potential impact of this hypothesis on "eligibility" for aPZB, we queried our prospectively collected multi-institutional database for consecutive patients undergoing surgery for nonmetastatic renal masses (cT1-4 N0-1 M0) between 2015 and 2021 to identify ccRCC cases meeting the KEYNOTE-564 criteria. We stratified the patients using the risk-adapted model proposed by Stewart-Merrill et al (whereby stopping follow-up is warranted when the estimated risk of other-cause mortality [OCM] outweighs the estimated risk of RCC recurrence). Then we explored the proportion of patients whose follow-up could theoretically be stopped at 2, 5, 10, or 20 yr, for whom "eligibility" for aPZB might be more controversial. Overall, 1745 patients with ccRCC were included, of whom 419 (24%) met the KEYNOTE-564 criteria. The proportion of patients "not eligible" for aPZB because of higher probability of OCM than of RCC recurrence would have been 81%, 66%, 43%, and 29% at "recommended" follow-up of ≤2.0, ≤5, ≤10, and ≤20 yr, respectively. To the best of our knowledge, this is the first study providing insights to support shared decision-making regarding eligibility for aPZB for patients with nonmetastatic ccRCC with a focus on patient-related factors beyond tumour-driven prognostic scores. PATIENT SUMMARY: An immunotherapy drug call pembrolizumab given after surgery for nonmetastatic kidney cancer may benefit some patients who have a high risk of disease recurrence, but it can have immune-related side effects. We found that comparing the risk of death from other causes and the risk of cancer recurrence could help in reducing overtreatment of patients who might not benefit from this drug.
引用
- Campi R, Pecoraro A, Roussel E, et al. Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study. Eur Urol Oncol. 2023. PMID: 37945489. doi:10.1016/j.euo.2023.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。